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Introduction
Malaria is a serious and sometimes fatal disease with 
an estimated 243 million new cases and 863,000 deaths 
annually worldwide (WHO, World Malaria Report 2009). 
Increasing drug resistance has lead to a demand for 
novel antimalarial treatments, most notably artemisinin 
combination therapies (ACTs). ACTs consist of a short-
acting potent artemisinin derivative combined with a 
long-acting partner drug to minimize the risk of sub-
therapeutic antimalarial levels which select for resistant 
mutants (Myint et al. 2007). Piperaquine (PQ; Figure 1) is 
a bisquinoline drug with a similar proposed mechanism 
of action as other quinoline antimalarials (Davis et al. 
2005). PQ is now available as a component of the ACT, 
dihydroartemisinin-piperaquine (DHA-PQ; Artekin™). 
DHA-PQ has been shown in clinical trials to be safe 
and highly effective in the treatment of uncomplicated 
malaria caused by Plasmodium falciparum or vivax 
(Hung et al. 2004; Karunajeewa et al. 2008). Recently, the 
World Health Organization (WHO) has added DHA-PQ 
to the list of 1st-line treatment options for uncomplicated 
P. falciparum malaria (World Health Organization 
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1.  Piperaquine (PQ) is part of a first-line treatment regimen for Plasmodium falciparum malaria recommended by 
the World Health Organization (WHO). We aimed to determine the major metabolic pathway(s) of PQ in vitro. A 
reliable, validated tandem mass spectrometry method was developed. Concentrations of PQ were measured after 
incubation with both human liver microsomes (HLMs) and expressed cytochrome P450 enzymes (P450s).
2.  In pooled HLMs, incubations with an initial PQ concentration of 0.3 µM resulted in a 34.8 ± 4.9% loss of substrate 
over 60 min, corresponding to a turnover rate of 0.009 min−1 (r2 = 0.9223). Miconazole, at nonspecific P450 
inhibitory concentrations, resulted in almost complete inhibition of PQ metabolism.
3.  The greatest inhibition was demonstrated with selective CYP3A4 (100%) and CYP2C8 (66%) inhibitors. Using a 
mixture of recombinant P450 enzymes, turnover for PQ metabolism was estimated as 0.0099 min−1; recombinant 
CYP3A4 had a higher metabolic rate (0.017 min−1) than recombinant CYP2C8 (p < .0001).
4.  Inhibition of CYP3A4-mediated PQ loss was greatest using the selective inhibitor ketoconazole (9.1 ± 3.5% loss 
with ketoconazole vs 60.7 ± 5.9% with no inhibitor, p < .0001).
5.  In summary, the extent of inhibition of in vitro metabolism with ketoconazole (83%) denotes that PQ appears 
to be primarily catalyzed by CYP3A4. Further studies to support these findings through the identification and 
characterization of PQ metabolites are planned.
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2010). Despite the emerging prominent role of DHA-PQ 
in the management of malaria, scant data exists on its 
metabolic pathways.
Recent in vivo studies indicate that PQ exhibits mul-
tiphasic pharmacokinetics with a long terminal half-life 
(20 to 30 days) potentially associated with extensive tis-
sue binding (Hung et al. 2004; Röshammar et al. 2006; 
Karunajeewa et al. 2008). Based on the detection of a 
carboxylic acid metabolite (M1) and minor N-oxidation 
metabolite (M2) in the blood and urine, a pharmacoki-
netic study in two healthy adults postulated that PQ elim-
ination involved a combination of hepatic metabolism 
and renal excretion (Tarning et al. 2006). The major route 
of elimination was proposed as P450-mediated hydroxyl-
ation to hydroxy-piperaquine, followed by hydrolysis to 
an aldehyde, then oxidation by aldehyde dehydrogenase 
to yield M1. Demonstrating the route of metabolism can 
be used to determine if in vivo drug interaction studies 
are warranted. The in vitro studies described below were 
designed to identify the major P450 enzyme(s) involved 
in PQ metabolism.
Materials and methods
Materials
Chemicals
PQ tetraphosphate tetrahydrate (>99% purified by 
HPLC) was purchased from Yick-Vic Chemicals and 
Pharmaceuticals Ltd (Hong Kong, China; Figure 1). A PQ 
analogue (7-chloro-4-(4-{7-[4-(7-chloro-4-quinolinyl)-
1-piperazinyl] heptyl}-1-piperazinyl)quinoline) was 
selected as the internal standard (IS) (Singhal et al. 2007) 
and purchased from Ryan Scientific (Mt. Pleasant, SC; 
Figure 1). The P450 inhibitors miconazole, quinidine, 
ticlopidine and ketoconazole were purchased from Sigma 
Aldrich (St. Louis, MO). Sulfaphenazole and furafylline 
were purchased from BD Biosciences (San Jose, CA).
Human liver microsomes and recombinant enzymes
A mixture of purified P450 liver microsomes expressed 
from human-derived cDNA (Supermix©, protein 
content of 5.0 mg/mL) contained the following spe-
cific enzymes: CYP1A2, CYP2C9, CYP2C8, CYP2C19 
and CYP3A4. Individual cDNA expressed CYP3A4 
and CYP2C8 enzymes were derived from baculovirus-
infected cells (Supersomes©, contained protein con-
tents of 4.0 and 3.0 mg/mL, respectively). A mixture of 
150 donor human liver tissue fraction pools with equal 
gender (BD UltraPool HLM 150©) containing a pro-
tein content of 20 mg/mL were also utilized. All above 
enzymes and liver fractions were purchased from BD™ 
Biosciences (San Jose, CA) and stored at −70°C prior to 
experimentation.
Tandem mass spectrometry analysis
Liquid chromatographic tandem mass spectrometry method
Prior liquid chromatographic tandem mass spectrom-
etry (LC/MS/MS) methods for detecting PQ in plasma 
were modified for quantification in potassium phosphate 
buffer (Singhal et al. 2007; Lindegardh et al. 2008; Tarning 
& Lindegardh 2008). Analyte separation was conducted 
on twin PE series 200 micro LC pumps equipped with 
a PE series 200 autosampler (Perkin Elmer, Norwalk, 
Connecticut) using a ZORBAX® Eclipse XDB Narrow 
Bore C18 analytical column, 2.1 × 50 mm, 5 µm (Agilent 
Technologies, Santa Clara, CA). MS/MS detection was 
performed on a Triple stage quadrapole API 2000™ 
Mass Spectrometer (Applied Biosystems/MDS SCIEX, 
Foster city, CA) equipped with turbo spray ionization 
(TSI) delivering 2.5 mM ammonium bicarbonate pH 
9.9/methanol 1:4 (v/v) in isocratic mode at a flow rate of 
0.4 mL/min for 6.5 min at 25°C (Singhal et al. 2007). 
Injection volume was 10 µL. Before each injection, the 
needle was cleaned with two preinjection washes and 
after injection with two post-injection washes. Optimal 
MS parameters were chosen by direct infusion of each 
compound separately through the MS/MS detector at a 
concentration of 1 µg/mL in 1:1 MeOH: water with 0.25% 
formic acid. LC/MS/MS conditions were as follows: the 
ion pairs 535/288 for PQ and 591/205 for the IS. were 
selected for mass spectrometry acquisition in multiple 
reaction monitoring (MRM) mode, electrospray ioniza-
tion in positive mode, collision-activated dissociation 
gas of 4 psi, curtain gas of 25 psi, spray voltage of 5 bKV, 
ion source gas 1 (nitrogen) of 40 psi, ion source gas 2 
(nitrogen) of 70 psi and a declustering potential of 66 V, 
collision energy of 48 v for PQ and 75 v for the IS.
Analysis
Chromatographic data acquisition, peak integration 
and quantification were performed using the Analyst™ 
software package (version 1.3; Applied Biosystems/MDS 
SCIEX, Foster City, CA). Retention times for PQ and 
PQ-IS were 1.33 min and 4.5 min, respectively.
Calibration standards and validation
Each sample was spiked with 15 µL of IS working solution 
(10 µg/mL). Calibration standards consisting of 20, 50, 
Figure 1. Chemical structures of piperaquine and internal standard 
used in these studies.
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100, 200, 500, 750, and 1000 ng/mL were prepared from 
working solutions in 0.1% aqueous formic acid/acetonitrile 
1:1 (V/V). The upper limit of quantification was set to 
1000 ng/mL since higher concentrations produced carry-
over effects higher than 20% of the response for an LLOQ 
sample. The specificity of the method was examined by 
analyzing (n = 6) blank phosphate buffer samples which 
did not yield significant interference at the retention time 
of the analyte. Seven-point calibration standard curves 
were calculated and fitted by 1/x weighted linear regression 
of the peak-area ratio of PQ to IS versus the concentration 
of PQ in each standard sample. Linear calibration curves 
were established over the range of 20–1000 ng/mL and a 
lower limit of detection (LLOD) was 10 ng/mL. This was the 
lowest concentration that could be reliably distinguished 
from background noise (≥3 times the S.D. of a blank plasma 
sample). The precision (CV %) and accuracy (dev %) of the 
back-calculated calibrator values over 3 days, ranged from 
1.6 to 9.6% and −6.7 to 4.3%, respectively. For intra- and 
interassay precision and accuracy, 5 replicates of validation 
samples at each of 4 different drug concentrations (20, 30, 
300, and 900 ng/mL) were analyzed on three separate days. 
A fresh calibration curve was used each day. The intraday 
precision (CV %) of this method for PQ ranged from 1.1 to 
3.1%, and the intraday accuracy (dev %) ranged from −4.8 
to 7.6%. The interassay precision (CV %) was 6.1, 5.6, 5.9, 
and 2.2%, respectively for LLOQ, low, medium, and high 
concentrations. The overall accuracy (% dev) from nominal 
value was 7.4, 3.3, 7.7, and −4.0% for LLOQ, low, medium, 
and high concentrations, respectively.
Stability studies
Due to the instability of PQ in glass, plastic Eppendorf© 
tubes were used for solution and sample preparation 
(Singhal et al. 2007). The stability of PQ and the PQ-IS 
stock solutions were evaluated in different tempera-
ture and timing conditions as follows. PQ (1 mg/mL) in 
0.1% formic acid/acetonitrile 1:1 (V/V) demonstrated 
stability after storage at −70°C for 21 days. The percent 
difference (3.59%) between the mean PQ peak area 
(4.81 × 106 cts, CV 3.68%) of the stored samples com-
pared to the mean peak area (4.64 × 106 cts, CV 0.69%) 
obtained from the fresh samples met FDA methods 
validation standards and the mean peak areas were not 
statistically different (p = .187).
To test for sample stability during processing, the 
peak area of PQ (750 µg/mL) stored at room tem-
perature for 24 h was compared to the PQ peak area of 
fresh samples (4.73, CV 3.623%) in 0.1% formic acid/
acetonitrile 1:1 (V/V) and determined to be equivalent 
(p = .3754). To examine the stability of the internal 
standard, PQ-IS samples (1.75 µg/mL) were stored in 
triplicate at 22°C in 0.1% formic acid/acetonitrile 1:1 
(V/V) for 7 days. The percent difference of the mean 
peak areas of stored compared to fresh samples was 
acceptable (0.51%) and peak areas were statistically 
similar (p = .320).
Incubations
Oxidative metabolism of PQ in pooled microsomal fractions
Working solutions of PQ and PQ-IS were prepared in 0.1% 
aqueous formic acid/acetonitrile 1:1. P450-dependent 
metabolism of PQ was explored based on previously pub-
lished methods and current industry guidance (Störmer et 
al. 2000b; Harper & Brassil 2008). Briefly, pooled human 
P450 microsomes, PQ, 0.4 U/L glucose-6-phosphate 
dehydrogenase (G6PDH) and cytochrome b5 were prein-
cubated in 0.10 M potassium phosphate buffer (pH 7.4) at 
37.5°C for 5 min. Reactions were initiated by addition of 
1.3 mM NADP+ and 3.3 mM glucose-6-phosphate (G6P) 
to achieve a final PQ concentration of 0.3 µM or 2 µM, 
HLM concentration of 0.1 mg/mL, and volume of 125 µL. 
Reactions proceeded at 37.5°C and were terminated at 
designated time points (0, 1, 15, 30, 45, or 60 min) by addi-
tion of 62.5 µL ice-cold acetonitrile and placement on ice 
for 5 min. Reactions were run in the absence of enzyme as 
negative controls. All reactions were run in triplicate.
Heat inactivation of flavin monooxygenases in  
microsomal fractions
In order to rule out flavin monooxygenase (FMO)-
mediated N-oxidation, a heat inactivation study was 
conducted. Incubations detecting oxidative metabolism 
of PQ in HLMs were modified by including a preincuba-
tion at 50°C for an additional 2 min (Rodrigues 2007). 
Reactions in triplicate were terminated at designated 
time points (0, 1, 30, and 60 min).
Cytochrome P450 inhibition in microsomal fractions
In order to determine the role of cytochrome P450 
enzymes in PQ metabolism, miconazole was utilized 
at concentrations at which it acts as a nonspecific P450 
inhibitor (5 µM) (Zhang et al. 2002). In order to char-
acterize the specific P450 isoforms responsible for the 
metabolism of PQ, isoform selective inhibition was con-
ducted based on industry standard inhibitors (Kajosaari 
et al. 2005; Harper & Brassil 2008). For nonmechanism 
based inhibition, the protocol for oxidative metabolism 
in HLMs was modified to achieve a final PQ concentra-
tion of 0.6 µM with standard inhibitors (5 µM quinidine, 
25 µM quercetin, 20 µM sulfaphenazole or 1 µM keto-
conazole) (Jancová et al. 2007; Harper & Brassil 2008). 
Reactions were incubated in triplicate at 37.5°C then 
terminated at 0, 1, 30 and 60 min.
Mechanism based inhibitors required an activation 
step involving preincubation of working mixtures (Kunze 
& Trager 1993; Donahue et al. 1997; Ko et al. 2000; Harper 
& Brassil 2008). Inhibitor working mixtures containing 
PQ, 0.1 mg/mL BD UltraPool HLM 150©, 1.3 mM NADP+, 
0.4 U/mL G6PDH, 3.3 mM G6P, a standard inhibitor 
(100 µM furafylline or 25 µM ticlopidine) in 0.10 M 
potassium phosphate buffer (pH 7.4) were incubated for 
30 min at 37.5°C. Working mixture aliquots (25 µL) were 
removed then preincubated for 5 min with 0.1 mg/mL 
human recombinant P450 microsomes (BD UltraPool 
CYP3A4-mediated piperaquine metabolism 1091
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HLM 150©), 1.3 mM NADP+, 0.4 U/mL G6PDH, 3.3 mM 
G6P and a standard inhibitor (furafylline or ticlopidine) in 
0.10 M potassium phosphate buffer (pH 7.4) at 37.5°C. The 
mixture was aliquoted into separate tubes then initiated 
with PQ to achieve a final substrate concentration of 0.6 
µM, inhibitor concentration of 20 µM furafylline or 5 µM 
ticlopidine and volume of 125 µL. Reactions in triplicate 
were incubated at 37.5°C then terminated at 0, 1, 30, and 
60 min.
Oxidative metabolism of PQ in cDNA expressed enzymes
A second in vitro metabolic system utilized cDNA 
expressed enzymes according to published guidelines 
(Harper & Brassil 2008; Störmer et al. 2000a; Food and 
Drug Administration, 2001). Preincubation mixtures 
contained 1.25 pmol (0.025 mg/mL) human recombinant 
P450 microsomes, PQ, and 0.4 U/mL G6PDH in 0.10 M 
potassium phosphate buffer (pH 7.4). NADP+ (1.3 µM) 
and 3.3 mM G6P were added to initiate the reaction. PQ 
metabolism was studied at 2 µM and 0.2 µM concentra-
tions. Reactions were incubated at 37.5° then terminated 
at 0, 1, 15, 30, and 60 min by addition of 62.5 µL ice-cold 
acetonitrile. Reactions were run in triplicate. Assays were 
also conducted containing individually expressed recom-
binant P450 enzymes (Supersomes©). The procedure for 
oxidative metabolism of PQ in recombinant P450s was 
modified to achieve a final PQ concentration of 0.2 µM 
and a microsomal content of 0.625 pmol (0.02 mg/mL) 
CYP3A4 or 0.625 pmol (0.015 mg/mL) of CYP2C8.
Selective P450 inhibition studies with cDNA expressed 
enzymes
To confirm the metabolic findings with recombinant 
P450s, a CYP3A4 selective inhibition assay was con-
ducted (Harper & Brassil 2008). Incubation assays 
containing human recombinant CYP3A4 microsomes 
(Supersomes©) were modified with the addition of the 
selective inhibitor ketoconazole. The final reagent con-
centrations in the incubation were 0.2 µM PQ and 1 µM 
ketoconazole. Reactions were run in triplicate.
Sample processing
For incubation of samples with high initial PQ concen-
trations (2 µM), a 1:4 dilution was conducted using 0.1% 
aqueous formic acid/acetonitrile 1:1 (v/v). No dilution 
was conducted for samples with a lower initial concen-
tration. An aliquot of the sample (70 µL) was mixed with 
15 µL of IS working solution (10 µg/mL) in 200 µL HPLC 
microvials and 10 µL was injected for LC/MS/MS analy-
sis. Each level of the calibration curve was measured with 
two sets of calibrators, one at the start and one at the end 
of the run.
Data analysis
For oxidative metabolism studies, loss of substrate of the 
parent drug >20% over a 60 min incubation was fitted 
using nonlinear regression; loss <20% was fitted using 
linear regression (Harper & Brassil 2008). For inhibition 
studies, the extent of inhibition was calculated (shown 
in the equation below). The Student’s t-test was used to 
evaluate the percent loss of substrate with FMO inac-
tivation compared with negative controls, net loss of 
PQ with individual recombinant enzymes, and percent 
loss of PQ in recombinant CYP3A4 inhibition studies. 
ANOVA was used to evaluate the net loss of PQ in the 
presence of nonselective and selective inhibitors.
Extentof inhibition
PQ PQ
PQ
control inh
control
(%)
[ ] [ ]
[ ]
=
∆ ∆
∆
−
×100%
Results
Metabolism studies in human liver microsomes
Substrate depletion studies in human liver microsomal 
fractions
In order to determine whether or not enzymes present in 
human liver microsomal (HLM) fractions were involved 
in PQ metabolism, substrate depletion studies were per-
formed with a donor pool of HLMs. Loss of PQ (0.3 µM 
starting concentration) was 34.8 ± 4.9% over 60 min. A 
nonlinear regression fit of the substrate concentration 
over time yielded a rate of degradation of k = 0.009 min−1 
(r2 = 0.922) (Figure 2).
Figure 2. Log transformed piperaquine depletion curves 
from human liver microsome studies. The initial piperaquine 
concentration was 0.27 µM and data shown are means ± SD of 
triplicate determinations. Nonlinear regression fitting yielded an 
estimated rate constant of 0.009 min−1.
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Role of cytochrome P450s and flavin monooxygenases in the 
metabolism of PQ
Given the evidence of substrate depletion in whole HLM 
fractions, we attempted to ascertain the specific enzyme 
groups involved in drug biotransformation. Miconazole 
(5 µM) was utilized in HLM incubations at concentrations 
where nonspecific P450 inhibition has been noted (Zhang 
et al. 2002). The percent inhibition of PQ metabolism was 
100% with miconazole at nonselective concentrations 
(data not shown).
Heating of HLM fractions allowed us to ascertain the 
role of flavin monooxygenases (FMOs) in PQ metabo-
lism. Thermal inactivation of FMOs did not significantly 
alter PQ depletion (47.9% versus 34.6% depletion at 
60 min, respectively; p = .59).
Selective inhibition of P450 isoforms in human liver 
microsomal fractions
The above studies suggested a role for P450 enzymes, 
but not FMOs, in the metabolism of PQ. As a next step, 
P450 isoform selective inhibition studies were under-
taken. Industry standard inhibitors were utilized in HLM 
incubations at recommended concentrations and sub-
strate depletion was assessed (Figure 3). The 95% con-
fidence intervals of % PQ remaining for the incubations 
with ticlopidine (CYP2C19 inhibitor), sulfaphenazole 
(CYP2C9 inhibitor) and furafylline (CYP1A2 inhibitor) 
overlapped with the control (no inhibitor) at 30 and 60 
min. However, ketoconazole (more selective for CYP3A4 
at a concentration of 1 µM) and quercetin (CYP2C8 
inhibitor) exhibited 100% and 66% inhibition of PQ 
(0.6 µM) metabolism, respectively. Incubations with 
quinidine (CYP2D6 inhibitor) showed an average 15% 
inhibition at high PQ initial concentrations, however 
results were not statistically significant.
Studies of PQ metabolism by cDNA expressed 
enzymes
Role of recombinant P450s (Supermix) in the  
metabolism of PQ
To provide supporting evidence for the role of cyto-
chrome P450s in the metabolism of PQ, P450 reaction 
phenotyping was conducted with recombinant cDNA 
expressed P450 enzymes. PQ incubation in the pres-
ence of a mixture of P450 enzymes (CYP1A2, CYP2C9, 
CYP2C8, CYP2C19 and CYP3A4) revealed a 20% loss of 
parent drug at 2 µM and 46% loss at 0.2 µM. The rate 
constants describing PQ metabolism were 0.0037 and 
0.0099 min−1 at high (2 µM) and low (0.2 µM) initial 
concentrations, respectively (Figure 4).
Figure 3. The effect of isoform selective P450 inhibitors on 
piperaquine metabolism. The data is expressed as percent 
piperaquine remaining (mean ± SD of triplicate determinations) as 
a function of time following human liver microsome incubations 
in the presence of isoform selective P450 inhibitors. The starting 
concentration of piperaquine was 0.6 µM. The following 
concentrations of inhibitors were used: 1 µM ketoconazole 
(CYP3A4), 5 µM ticlopidine (CYP2C19), 20 µM furafylline (CYP1A2), 
20 µM sulfaphenazole (2C9), and 25 µM quercetin (CYP2C8).
Figure 4. Log transformed piperaquine depletion curves from 
incubation with a mixture of recombinant P450 isoforms. Data 
shown are means ± SD of triplicate determinations. Nonlinear 
regression fitting yielded estimated rate constants of 0.0037 
min−1 and 0.0099 min−1 for 2 and 0.2 µM piperaquine initial 
concentrations, respectively.
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Role of recombinant CYP3A4 and CY2C8 in the  
metabolism of PQ
Based on data obtained from HLM and a mixture of 
recombinant P450s, further testing was conducted 
using individual recombinant P450 isoforms. Less than 
20% PQ depletion was observed for incubations with 
CYP2C8, yielding an estimated turnover rate of 0.0001 
min−1 (Figure 5). The corresponding rate constant for 
CYP3A4 was 0.017 min−1. The difference between the 
net decrease in PQ concentration in CYP3A4 (118.0 ± 
4.5 nM) and CYP2C8 (10.0 ± 14.3 nM) incubations was 
statistically significant (p < .0001).
The higher rate of PQ metabolism by CYP3A4 com-
pared to CYP2C8 prompted further exploration using 
CYP3A4 selective inhibitors. PQ depletion over 60 min 
was only 9.1 ± 3.5% in the presence of 1 µM ketoconazole 
compared to 60.7 ± 5.9% without inhibitor (Figure 6, 
p < .0001). The extent of inhibition by ketoconazole was 
calculated as 83%.
Discussion
We developed and validated a LC/MS/MS method for 
the quantification of PQ for in vitro studies. Using this 
method, we determined that in vitro PQ metabolism 
was mediated by cytochrome P450 pathways, primarily 
by CYP3A4. Our initial studies in pooled HLMs showed a 
35 ± 5% loss of PQ over 60 min, corresponding to a 
turnover rate of 0.009 min−1 (r = 0.922). After demonstrat-
ing that the loss of PQ in HLMs was likely due to the action 
of P450 enzymes, and not FMO-mediated N-oxidation, we 
went on to characterize the effect of CYP isoform selective 
inhibitors. The greatest degree of inhibition was demon-
strated with CYP3A4 (100%) and CYP2C8 (66%) selec-
tive inhibitors. Using a mixture of recombinant P450s, at 
least 30% PQ loss was demonstrated over 60 min with an 
estimated turnover number of 0.0099 min−1. Individual 
recombinant enzyme studies supported CYP3A4 as the 
major enzyme catalyzing PQ metabolism.
Our in vitro studies utilized measurement of substrate 
depletion to identify the major enzymes involved in PQ 
metabolism. Although potential metabolites have been 
described in the literature, these entities have not been 
extensively characterized and are not readily available 
(Tarning et al. 2006). FDA guidelines and current industry 
standards for drug development recommend at least two 
in vitro methods be performed to confirm metabolism 
(Bjornsson et al. 2003; Harper & Brassil 2008). Pooled 
human liver microsomes and cDNA expressed enzymes 
were utilized in these studies. In both systems, greater 
than 30% loss of PQ is consistent with P450 metabolism. 
While beyond the scope of this paper, we plan to extend 
these studies by definitively characterizing in vitro and 
in vivo metabolites of PQ.
A few points regarding the data warrant further 
discussion. Quercetin, a CYP2C8 inhibitor, exhibited 
Figure 5. Log transformed piperaquine depletion curves from 
incubation with recombinant CYP3A4 or CYP2C8. Data shown 
are means ± SD of triplicate determinations. Nonlinear regression 
fitting yielded estimated rate constants for CYP2C8 and CYP3A4 
metabolism of 0.001 and 0.017 min−1 respectively.
Figure 6. The effect of ketoconazole on piperaquine metabolism. 
The data is expressed as percent piperaquine remaining (mean 
± SD of triplicate determinations) as a function of time following 
incubations with recombinant CYP3A4 in the presence or absence 
of ketoconazole (1 µM).
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the second highest extent of inhibition in our HLM 
studies at high and low parent drug concentrations, 66% 
and 59% respectively, and may represent a secondary 
metabolic pathway. However, CYP3A4 recombinant 
enzymes yielded the fastest turnover of PQ and this 
was significantly greater than turnover by CYP2C8. The 
inhibition studies with ketoconazole further support 
this conclusion. Collectively, these findings suggest 
that CYP3A4 is the major CYP enzyme involved in PQ 
metabolism. However, it remains possible that PQ 
could also be significantly metabolized by CYP2C8 in 
vivo, especially in the setting of CYP3A4 inhibition. Our 
findings are consistent with a lower Km of PQ for CYP3A4 
than for CYP2C8. It is also possible that 0.2 µM PQ far 
exceeds the Km for both enzymes and a higher V
max
 for 
CYP3A4 accounts for the significant metabolism through 
this pathway; this is less likely since typical incubations 
range between 1–10 µM. Further studies may be needed 
to elucidate the importance of the CYP2C8 pathway. The 
relative importance of gut and liver CYP3A4, particularly 
for first pass metabolism, will also require further studies.
CYP2D6 may also represent a minor metabolic path-
way for PQ. Although our results were highly variable, 
quinidine (CYP2D6-specific inhibitor) showed 15% inhi-
bition of PQ depletion at high initial concentrations. While 
the preparation of HLMs from 150 donors should have 
minimized the effect of 2D6 polymorphisms on metabolic 
activity, it is known that the variability of CYP2D6 makes 
it a difficult enzyme to characterize in vitro. CYP2D6 was 
not investigated further, as it was felt to be a minor path-
way in comparison to 3A4 or 2C8 (Harper & Brassil 2008).
While our study utilized two approaches, it is clear that 
in vitro studies can not sufficiently address the complexi-
ties of human physiology involved in drug metabolism. It 
is difficult to simulate the actual in vivo ratio of enzyme 
to substrate concentrations, competition for the active 
site between alternate xenobiotics or biosynthetic inter-
mediates, and evaluate for population variation of P450 
enzymatic activity. Based on the structure of PQ and the 
recent identification of potential metabolites detected in 
urine, we and others postulated that P450 or FMO bio-
transformation may be likely modes of biotransformation 
(Tarning et al. 2006). Conversely, uridine 5′-diphospho-
glucuronosyltransferases (UGTs) do not appear to likely 
play a major role in PQ metabolism, as no PQ glucuronide 
conjugates were isolated from previous urinary analysis 
(Tarning et al. 2006). However, it remains possible that 
other unidentified metabolites may be present.
conclusions
With the addition of DHA-PQ to the list of 1st-line antima-
larials, and the exceptional efficacy seen in recent studies, 
it is estimated that millions of doses of DHA-PQ will be dis-
pensed annually. Surprisingly, despite this potential wide-
spread use, knowledge of the biotransformation of this drug 
and its potential for drug–drug interactions has not been 
characterized. Our studies reveal that CYP3A4 metabolism, 
either in the liver or gut mucosa, is a potential pathway for 
PQ elimination. CYP3A4 is responsible for numerous clini-
cally relevant drug–drug interactions. Thus, although our 
in vitro findings support only a moderate role for CYP3A4 
in PQ metabolism, we feel that further investigation into 
whether these findings translate into meaningful in vivo 
interactions is warranted. We and others have recently 
demonstrated that several antiretrovirals, notably CYP3A4 
inhibiting protease inhibitors, and CYP3A4-inducing non-
nucleoside reverse transcriptase inhibitors can have potent 
effects on CYP3A4-mediated antimalarial metabolism 
(Slutsker & Marston 2007; German et al. 2009; Katrak et al. 
2009). It will be prudent to investigate whether or not PQ 
will be subject to similar effects to these and other coad-
ministered medications. Similarly, given the long half-life 
of PQ, it will be prudent to examine the potential inductive 
or inhibitory effects of PQ on major CYP isoforms. Further 
studies to characterize the in vivo metabolites of PQ, along 
with studies of the potential modulatory effects of PQ on 
CYP enzymes are planned.
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